CordenPharma Increases Sterile Injectable Manufacturing Capacity to 500 Million Units Annually

CordenPharma is significantly increasing its sterile injectable manufacturing capacity, boosting annual output to 500 million units. The company announced an €80 million investment for a new facility and additional aseptic fill-finish lines, aimed at meeting growing global demand.

The expansion is designed to enhance production efficiency and meet stringent Good Manufacturing Practice (GMP) standards. This capital expenditure supports CordenPharma's strategy to solidify its role as a Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical sector.

The new lines are expected to enable larger batch production and reduce lead times for clients. The increased capacity aims to support the launch of new therapies and improve supply chain resilience worldwide. While the investment is multi-year, specific completion timelines were not disclosed.

CordenPharma specializes in pharmaceutical development and manufacturing services, with a focus on complex sterile injectables. The company seeks to address the pharmaceutical industry's need for reliable, high-capacity manufacturing partners.